Checkpoint inhibitor

Resistance to Immunotherapy in Patients with Urothelial Bladder Cancer Is Traced to Specific Sets of Immune Cells

Retrieved on: 
Friday, April 9, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Cancer, Immune system, Immunotherapy, Virotherapy, Checkpoint inhibitor, Bladder cancer, Tumor microenvironment, Transitional cell carcinoma, Immune checkpoint

NEW YORK, April 9, 2021 /PRNewswire-PRWeb/ -- Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai.

Key Points: 
  • NEW YORK, April 9, 2021 /PRNewswire-PRWeb/ -- Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai.
  • The researchers then identified specific cells in the tumor microenvironment associated with resistance to immune checkpoint blockade, and potential targets for therapies designed to overcome resistance.
  • The research is among the first to use both bulk and single-cell RNA sequencing of human bladder tumors to study resistance to immunotherapy.
  • "Our research shows that a specific cellular state of myeloid cells underlying pro-tumorigenic inflammation account for resistance to immune checkpoint blockade in a very large percentage of patients with urothelial bladder cancer," Dr. Galsky says.

Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates

Retrieved on: 
Friday, April 9, 2021
Immune system, Clusters of differentiation, Branches of biology, Cancer immunotherapy, Checkpoint inhibitor, Colony stimulating factor 1 receptor, Immune checkpoint, Programmed cell death protein 1, Health care, Protein kinase inhibitors

For MET/SRC/CSF1R inhibitor TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors.

Key Points: 
  • For MET/SRC/CSF1R inhibitor TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors.
  • With the new data, Turning Point is evaluating a potential additional combination study of TPX-0022 and an anti-PD-1 checkpoint inhibitor.
  • Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics drug candidates, the results, conduct, progress and timing of Turning Point Therapeutics pre-clinical studies and plans regarding future development activities.
  • Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, April 9, 2021
Clusters of differentiation, Clinical medicine, Medical specialties, Medicine, Cancer immunotherapy, Immune system, PD-L1, PD-1 and PD-L1 inhibitors, Programmed cell death protein 1, L1, Checkpoint inhibitor, Cancer immunology

MOUNTAIN VIEW, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Companys orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research (AACR).

Key Points: 
  • MOUNTAIN VIEW, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Companys orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research (AACR).
  • The poster presentation, which showcases CCX559s ability to induce anti-tumor immunity, will go live on Saturday, April 10 at 8:30 a.m.
  • PD-L1/PD-1 interaction is one of the major checkpoints that limit effector T cell function against cancer cells.
  • The study featured in the AACR poster presentation demonstrated that CCX559 potentially employs distinct mechanisms to inhibit PD-L1 compared to the anti-human PD-L1 antibodies.

Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021

Retrieved on: 
Friday, April 9, 2021
Medical specialties, Clinical medicine, Medicine, Immune system, Immunology, Biotechnology, Monoclonal antibody, Checkpoint inhibitor, Antibody

Details are as follows:

Key Points: 
  • Details are as follows:
    Title of Presentation:Targeting SIRP with APX701, a Novel Myeloid Checkpoint Inhibitor (Abstract ID LB177)
    The posters will be available on the e-poster website from at 8:30 am EDT on April 10, 2021, through June 21, 2021.
  • APX005M and Apexigen's other programs were discovered using Apexigen's proprietary APXiMAB discovery platform.
  • This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies.
  • Seven product or product candidates discovered using APXiMAB are currently commercially available or in clinical development, either internally by Apexigen or by its licensees.

MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment

Retrieved on: 
Friday, April 9, 2021
Science, Biotechnology, Research, Oncology, Health, Medical devices, Clinical trials, Other Health, Branches of biology, Gene expression, RNA, RNA activation, Biology, American Association for Cancer Research, Cancer research, Checkpoint inhibitor, CEBPA

MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced translational data supporting the favourable immunological effects of MTL-CEBPA and its benefits in combination with other cancer therapies including anti-PD1 checkpoint inhibition.

Key Points: 
  • MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced translational data supporting the favourable immunological effects of MTL-CEBPA and its benefits in combination with other cancer therapies including anti-PD1 checkpoint inhibition.
  • The data will be presented during a poster session at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually from April 10 - April 15, 2021.
  • "These new translational findings confirm the important role of MTL-CEBPA in cancer immunology," said Robert Habib, CEO of MiNA Therapeutics.
  • The results validate and expand on previously presented pre-clinical research findings on MTL-CEBPA as an immunological combination treatment in liver cancer and colon cancer .

TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors

Retrieved on: 
Thursday, April 8, 2021
Research, Venture capital, Professional services, Biotechnology, Health, General Health, Other Science, Science, Oncology, Clinical medicine, Medicine, Cancer immunotherapy, Medical specialties, Virotherapy, Oncology, Immunotherapy, Checkpoint inhibitor, Melanoma, TriSalus, MD Anderson

Were pleased to collaborate with MD Anderson in pursuit of our collective goal to improve outcomes for patients with tumors of the liver and pancreas.

Key Points: 
  • Were pleased to collaborate with MD Anderson in pursuit of our collective goal to improve outcomes for patients with tumors of the liver and pancreas.
  • Our collaboration with TriSalus provides a unique opportunity to evaluate immunotherapy in combination with a novel delivery approach, said Sapna Patel, M.D., associate professor of Melanoma Medical Oncology at MD Anderson.
  • TriSalus Life Sciences is a revenue generating, emerging immuno-oncology company dedicated to developing immunotherapy treatments for liver and pancreatic tumors using novel delivery technologies to improve patient outcomes.
  • In combination with checkpoint inhibitors, TriSalus focus is to reprogram the dominant immunosuppressive cell population in liver and pancreatic tumors.

Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, April 6, 2021
Cancer immunotherapy, Medicine, Clinical medicine, Checkpoint inhibitor, Immunotherapy, Melanoma

Lars Wegner, CEO of Evaxion, said: Evaxion made outstanding progress in 2020 in redefining the immunotherapy discovery process through our AI platform technologies, despite the complications caused by the COVID-19 pandemic.

Key Points: 
  • Lars Wegner, CEO of Evaxion, said: Evaxion made outstanding progress in 2020 in redefining the immunotherapy discovery process through our AI platform technologies, despite the complications caused by the COVID-19 pandemic.
  • In 2020, we initiated a Phase 1/2a clinical trial of the adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma.
  • This provides funding to advance our four product candidates into 2022, covering a number of key expected milestones.
  • Evaxion will host a webcast and conference call today, April 6, 2021, at 8.30 a.m. EDT.

Immunotherapy Drugs Industry Assessment 2021 Featuring Comprehensive Profiles of Amgen, Bayer, Johnson & Johnson, Novartis, Pfizer, and Other Major Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 1, 2021
Health, Pharmaceutical, Clinical medicine, Medicine, Medical specialties, Cancer immunotherapy, Immune system, Immunology, Immunotherapy, Virotherapy, Cancer treatments, Checkpoint inhibitor, Monoclonal antibody

The "Immunotherapy Drugs: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immunotherapy Drugs: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The global immunotherapy market can be segmented into the following types: checkpoint inhibitors, monoclonal antibodies, interferons and interleukins.
  • The monoclonal antibodies segment accounted for the largest share of the global market for immunotherapy drugs in 2019.
  • It also explains the major drivers and regional dynamics of the global market and current trends within the industry.

Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation

Retrieved on: 
Wednesday, March 31, 2021
Health sciences, Medicine, Clinical medicine, Clinical research, Hepatology, Drug discovery, Pharmaceutical industry, Cholangiocarcinoma, Clinical trial, Checkpoint inhibitor

In the summer of 2018, the Company amended the protocol for the FOCUS trial to a single arm design.

Key Points: 
  • In the summer of 2018, the Company amended the protocol for the FOCUS trial to a single arm design.
  • The checkpoint inhibitor ORR was calculated based on a meta-analysis covering 16 different publications and 476 patients.
  • In addition to the FOCUS Trial which is investigating the treatment of mOM, we have initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC) called the ALIGN Trial.
  • We have paused our work on the ALIGN Trial while we reevaluate the trial design.

Global Immunotherapy Drugs Market Outlook 2021-2025 - Short & Long-term Impact of COVID-19, Delayed Approvals for Non-COVID-related Pharmaceutical Products, Changes in Consumption Trends

Retrieved on: 
Wednesday, March 31, 2021
Clinical medicine, Medicine, Medical specialties, Cancer immunotherapy, Immune system, Immunology, Immunotherapy, Virotherapy, Cancer treatments, Checkpoint inhibitor, Monoclonal antibody

DUBLIN, March 31, 2021 /PRNewswire/ -- The "Immunotherapy Drugs: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 31, 2021 /PRNewswire/ -- The "Immunotherapy Drugs: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The global immunotherapy market can be segmented into the following types: checkpoint inhibitors, monoclonal antibodies, interferons and interleukins.
  • The monoclonal antibodies segment accounted for the largest share of the global market for immunotherapy drugs in 2019.
  • It also explains the major drivers and regional dynamics of the global market and current trends within the industry.